These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9783563)

  • 41. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder.
    Pato MT; Pigott TA; Hill JL; Grover GN; Bernstein S; Murphy DL
    Am J Psychiatry; 1991 Jan; 148(1):127-9. PubMed ID: 1984696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous chlorimipramine therapy in obsessive-compulsive disorder.
    Warneke L
    Can J Psychiatry; 1989 Dec; 34(9):853-9. PubMed ID: 2611753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy of obsessive-compulsive disorder.
    Klein DF
    Encephale; 1990; 16 Spec No():331-4. PubMed ID: 2209491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clomipramine in obsessive-compulsive disorder.
    Katz RJ; DeVeaugh-Geiss J; Landau P
    Biol Psychiatry; 1990 Sep; 28(5):401-14. PubMed ID: 2207219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response versus remission in obsessive-compulsive disorder.
    Simpson HB; Huppert JD; Petkova E; Foa EB; Liebowitz MR
    J Clin Psychiatry; 2006 Feb; 67(2):269-76. PubMed ID: 16566623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.
    Hewlett WA; Vinogradov S; Agras WS
    J Clin Psychopharmacol; 1992 Dec; 12(6):420-30. PubMed ID: 1474179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary free cortisol levels in obsessive-compulsive disorder.
    Gehris TL; Kathol RG; Black DW; Noyes R
    Psychiatry Res; 1990 May; 32(2):151-8. PubMed ID: 2367600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S; Quercioli L; Paiva RS; Koran LM
    Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
    DeVeaugh-Geiss J; Landau P; Katz R
    Psychopharmacol Bull; 1989; 25(1):36-40. PubMed ID: 2672070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous anti-obsessive agents: a review.
    Ravindran LN; Jung SM; Ravindran AV
    J Psychopharmacol; 2010 Mar; 24(3):287-96. PubMed ID: 18801828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?
    Mundo E; Bareggi SR; Pirola R; Bellodi L
    Biol Psychiatry; 1999 Feb; 45(3):290-4. PubMed ID: 10023504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.
    Koran LM; Pallanti S; Paiva RS; Quercioli L
    Eur Neuropsychopharmacol; 1998 May; 8(2):121-6. PubMed ID: 9619690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The antiobsessional effects of clomipramine do not require concomitant affective disorder.
    Katz RJ; DeVeaugh-Geiss J
    Psychiatry Res; 1990 Feb; 31(2):121-9. PubMed ID: 2183254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.